← Search & browse all drugs
NERVOUS SYSTEM › PSYCHOANALEPTICS › ANTI-DEMENTIA DRUGS › Other anti-dementia drugs
aducanumab
N06DX03
Forms & Strengths
- Intravenous solution: 100 mg/mL (170 mg/1.7 mL single-dose vial)
- Intravenous solution: 100 mg/mL (328 mg/3.2 mL single-dose vial)
Adult Dosing
- Initial dose: 1 mg/kg IV infusion once every 4 weeks for the first two infusions
- Titration dose 1: 3 mg/kg IV infusion once every 4 weeks for the next two infusions
- Titration dose 2: 6 mg/kg IV infusion once every 4 weeks for the next two infusions
- Maintenance dose: 10 mg/kg IV infusion once every 4 weeks thereafter
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
Indications
- Treatment of Alzheimer's disease to reduce amyloid beta plaque accumulation
Mechanism of Action
- Humanized monoclonal antibody (IgG1 kappa) directed against aggregated forms of amyloid beta
Contraindications
- Known hypersensitivity to aducanumab or any of its excipients
Adverse Reactions
- Amyloid-related imaging abnormalities (ARIA-E with edema/effusion, ARIA-H with microhemorrhage/superficial siderosis)
- Headache
- Fall
- Confusional state
- Dizziness
Drug Interactions
- No formal pharmacokinetic drug interaction studies have been conducted
- Concomitant use of anticoagulants or antiplatelets may increase the risk of intracerebral hemorrhage
Curated Content: Needs Vetting Before Put to Clinical Use